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A series of N-1H-indazole-1-carboxamides has been synthesized and their effects on both CDK1 /
cyclin B and the K-562 (human chronic myelogenus leukemia) cell line were evaluated. Using a
computational model, we have observed that all the most active compounds 9e, f, i–n exhibited
the same binding mode of purvanalol A in the ATP-binding cleft. Although they were able to
moderately inhibit the leukemic cell line K-562 and to show inhibitory activity against the Cdc2-
Cyclin B kinase in the low micromolar range, they turned out to be non-cytotoxic against HuDe
(IZSL) primary cell cultures from human derm. These preliminary results are quite encouraging
in view of the low toxicity demonstrated by the above-mentioned compounds.
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Introduction
2,6,9-Substituted purine derivatives represent a class of
potent and selective inhibitors of cyclin-dependent pro-
tein kinase (CDK) that have recently been found to be of
potential use as anticancer drugs [1–3]. In particular, olo-
moucine 1 [4], roscovitine 2 [5], purvalanol A 3 [6], O6-
cyclohexylmethylguanine (NU2058) 4, and its analoge
NU61025 [7] are significant examples of such kind ofmol-
ecules (Fig. 1).
They act by competing with ATP for binding in the
CDK catalytic site located in a deep cleft between the two
lobes of the protein kinase [8].
Four key features are essential for the interaction with
CDKs, the presence of the flat hydrophobic purine ring
and the opportune substitutions in the position 2, 6, and
9. The purine ring allows the interaction of themolecules
with the hinge region, a flexible fragment consisting of
81 to 84 residues that connects the two lobes of the kin-
ases [9]. In particular, ATP adenine moiety hydrogen-
bonds the backbone oxygen of Glu81 and the backbone
nitrogen of Leu 83, and these hydrogen bonds are typi-
cally emulated by the CDK inhibitors that bind to the
hinge region; a third hydrogen bond to the backbone
oxygen of Leu 83 has also been observed for olomoucine
1, roscovitine 2, purvalanol A 3, and NU2058 4 [9, 10].
As a part of our research, we synthesized some N-(heter-
oaryl)-2-iodobenzamides 6a–p with the aim of ascertain
their activity as fungicides (Scheme 1) [11, 12].
Among the synthesized benzamides, the N-(indazol-3-
yl)benzamides 6o, p have drawn our attention as poten-
tial CDK inhibitors because they contain the characteris-
tic, common to the majority of CDK inhibitors, the capa-
bility to make hydrogen bonds with the molecular fork
present in the hinge region of CDKs [9] (Fig. 2).
On the basis of the structures of known potent CDK
inhibitors, we foresaw the following structural modifica-
tions on the N-(indazol-3-yl)benzamido skeleton: the
Correspondence: Prof. Demetrio Raffa, Dipartimento di Chimica e Tec-
nologie Farmaceutiche, Universit degli Studi di Palermo, Via Archirafi,
32, I-90123-Palermo, Italy.
E-mail: demraffa@unipa.it
Fax: +39 91 623 6117
i 2009WILEY-VCH Verlag GmbH &Co. KGaA,Weinheim
266 D. Raffa et al. Arch. Pharm. Chem. Life Sci. 2009, 342, 265–273
introduction of various substituents on the benzamido
moiety and its displacement from the 3-position of the
indazole nucleus to the 5- and 6-positions, the amidic
function inversion, and the substitution of the benz-
amido moiety with the phenoxyacetamido and phenyla-
cetamido ones, with the goal to identify potent low
molecular weight inhibitors of CDK1 that act by prevent-
ing the binding of the cofactor ATP to the enzyme. Molec-
ular modelling and docking studies of the synthesized
compounds were finally performed in order to rational-
ize the obtained CDK-inhibitory activities.
Results
Chemistry
The synthesis of N-(1H-indazol-3-yl)benzamides 9a [12],
9b–f, 9g [13], 9h [12], 9i [12], 9l–n, 9o [14], 3,4-dichloro-N-
(1H-indazol-5-yl)benzamide 11m [13], 3,4-dichloro-N-(1H-
indazol-6-yl)benzamide 13m, N-(1H-indazol-3-yl)-2-phe-
noxyacetamide 16, and N-(1H-indazol-3-yl)-2-phenylaceta-
mide 17 [12] was obtained starting from commercially
available benzoyl chloride precursors 7a–o, 14, 15, and
the opportune aminoindazole 8, 10, 12 as reported in
Scheme 2.
The synthesis of the N-(3,4-dichlorophenyl)-1H-inda-
zole-3-carboxamide 23 [15] and N-(5-chloro-2-iodophenyl)-
1H-indazole-3-carboxamide 24 were carried out accord-
ing to Scheme 3. The acylating agent diindazolo[2,3-
a,29,39-d]pyrazine-7,14-dione 21 was obtained as follows:
the 1H-indazole-3-carboxylic acid 18was reacted with thi-
onyl chloride as reported in the literature [16]. The 3,4-
dichloroaniline 20was purchased fromAldrich Chemical
Company (Germany) and was used as received. The start-
ing compound 5-chloro-2-iodoaniline 22 was obtained by
reacting the 3-chloroaniline 19 with N-iodosuccinim-
mide (NIS) in acetic acid [17].
The structures of new compounds were characterized
by analytical and spectroscopic measurements. The 1H-
NMR spectra of compounds 9, 11, 13, 16, 17 are consistent
with the N-(1H-indazolyl)benzamido structure [18]. The
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Figure 1. Chemical structures of some purine-derivative CDK
inhibitors.
Figure 2. Potential hydrogen-bonding interactions of N-(indazol-
3-yl)-benzamides with the hinge region.
Scheme 1. Synthetic pathway to obtain N-(heteroaryl)-2-iodo-
benzamides 6a–p.
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aromatic protons appeared as multiplets at d = 6.95 to
8.36 ppm, the benzamido NH protons appeared as sin-
glets at d = 10.49 to 11.14 ppm, while the indazole NH
protons were found at d = 12.68 to 13.04 ppm; com-
pounds 16 and 17 also showed a singlet at d = 4.82 ppm
(OCH2) and d = 3.40 ppm (CH2), respectively. The 1H-NMR
spectra of compounds 23 and 24 demonstrated a N-phe-
nyl-1H-indazole-3-carboxamide structure [15]. The aro-
matic protons appeared as multiplets at d = 7.29 to
8.36 ppm, the carboxamide NH protons appeared as sin-
glets at d = 10.69 to 10.71 ppm, while the indazole NH
protons were found at d = 13.86 to 13.88 ppm.
Molecular modellingmethods
The crystallographic structure of CDK1 has not yet been
determined, there is report of homology modelling of
CDK1 [19]. The comparison between the sequences of the
CDK1 and CDK2 proteins shows that these two proteins
share 66% of identity with a similarity of 84%. Moreover,
the sequence alignment and the contact shown that the
binding sites of these two enzymes are very similar [19–
21]. In particular, they present only two differences at
positions 84 and 85 in their amino acidic composition
which can be considered as minor difference, since their
chains project outside the ATP-binding pocket and are
not involved in ligand binding [20]. Furthermore, the
hydrogen bond nucleoside recognition site remains rela-
tively unchanged in the CDK1 model compared with the
CDK2 crystal structure with a RMS (root mean square)
deviation of the backbone on these residues of 0.23 
[19]. Finally, the molecular fork identified in CDK2 struc-
tures seems to be conserved in the CDK1 structure sug-
gesting that CDK1 may also be strongly inhibited by
CDK2 inhibitors [21].
Based on these informations, the human thr160-phos-
pho cdk2/cyclin A complexed with the inhibitor NU6102
5, which showed a resolution of 2.00  (Fig. 1; Broo-
khaven Protein Data Bank access code 1H1S) [22], was
selected for the performance of molecular docking
experiments
Insight II was used to check the 1H1S structure for
missing atoms, bonds, and contacts. Cerius2 4.10 was
used to add hydrogens to the enzyme structure, to man-
ually delete ligands and water molecules by saving only
those that are able to form hydrogen bonds with the
amino acids of the binding site (HOH5, HOH96, HOH120)
[22].
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Scheme 2. Synthetic pathway to obtain compounds 9a–o, 11m,
13m, 16, and 17.
Scheme 3. Synthetic pathway to obtain compounds 23 and 24.
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The structure of NU6102 5 (Fig. 1) was obtained with
Cerius2 4.10 by selecting and cutting the ligand from the
protein-ligand complex.
Structures of the designed derivatives 9a–o, 11m, 13m,
16, 17, 23, and 24were generated bymolecularmodelling
with Cerius2 4.10 software by optimizing their geometry
using the Dreiding 2.21 force field with Gasteiger
charges.
The active site of 1H1S was defined by the “docked
ligand” procedure in the program Cerius2 4.10 according
to the shape of the ligand NU6102 5 as grid points around
this one which are unoccupied by protein atoms. A rigid
docking experiment was performed for NU6102 5 and,
the ligand-fit predicted conformation of NU6102 5 shows
a high overlap with its x-ray crystallographic structure
with a RMS of 1.02.
All inhibitors were docked into the active site of 1H1S
to generate the docked conformations using the flexible
docking procedure of “ligand fit” in the program Cerius2
4.10.
Biology
CDK1 inhibitory activity
The CDK1 inhibitory activity for derivatives 9a–o, 11m,
13m, 16, 17, 23, and 24was determined in-house in a non-
radioisotopic assay (CycLex Cdc2-Cyclin B kinase assay
kit) using purvanolol A as reference compound. The
results as percent of CDK inhibition at 10 lM concentra-
tion are reported in Table 1. The IC50 values for com-
pounds that exhibit at least 50% of CDK inhibition at
screening concentration are reported in Table 2.
Tumour cell line screening
Synthesized N-(indazolyl)benzamido derivatives 9a–o,
11m, 13m, 16, 17, 23, and 24 were tested in vitro for their
antileukemic activity against the K-562 (human chronic
myelogenus leukemia) cell line. The results are reported
in Table 3 as percent of growth inhibition at 10 lM con-
centration.
Cytotoxicity for normal cells
To obtain more insights into the cytotoxic potential of
tested compounds for normal human cells, the com-
pounds 9e, f, i–nwere tested in vitro for their cytotoxicity
against HuDe (IZSL), primary cell cultures from human
derm (Table 4). All the tested compounds showed an IC50
greater than the cytotoxic activity on K-562.
Cell-cycle analysis
Because molecules exhibiting activity on CDK should
cause the alteration of cell-cycle parameters, the effects
of 9m on cell-cycle distribution was analyzed in K562
cells. Cells were cultured for 24 h in the presence of 9m
used at the cytostatic concentration evaluated after 24 h
of treatment (20 lM). Flow-cytometric analysis of the cell
cycle was carried out as described in Experimental (Sec-
tion 4.3.4) and reported in Fig. 3. The analysis of cell cycle
of K562 cells exposed 24 h to 9m showed a recruitment of
cells in the late S-phase and in G2 / M. This is consistent
with the ability of 9m to inhibit CDK1 which is involved
in the S-G2-M transition.
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Table 1. Percent inhibition of CDK1 at 10 lM concentration of
9a–o, 11m, 13m, 16, 17, 23, and 24.
Comp. 9a 9b 9c 9d 9e 9f 9g 9h 9i 9l
22.5 15.5 10.0 32.1 55.1 60.8 23.4 41.8 55.4 60.7
Comp. 9m 9n 9o 11m 13m 16 17 23 24 PUR
60.3 49.9 16.9 ns ns 10.0 ns ns ns 83.3
Values are the mean of at least three independent determina-
tions; coefficient of variation was less than 15%; ns = not signifi-
cant (%-inhibition a10%); PUR = purvanolol A.
Table 2. IC50 values for compounds 9e, f, i–n that exhibit at
least 50% of CDK inhibition at screening concentration.
Compound 9e 9f 9i 9l 9m 9n PUR
IC50 (lM) 6.6 4.4 8.8 9.8 6.0 10.0 1.8
Values are the mean of at least three independent determina-
tions; coefficient of variation was less than 15%; PUR = purvano-
lol A.
Table 4. IC50 values (lM) for compounds 9e, f, i–n that exhibit
at least 50% of inhibition on HuDe (IZSL), primary cell cultures
from human derm.
Comp. 9e 9f 9i 9l 9m
180 A200 A200 178 90
Values are the mean of at least three independent determina-
tions; coefficient of variation was less than 15%; ns = not signifi-
cant (% inhibition a10%).
Table 3. Percent-growth inhibition recorded on K562 cell line at
10 lM concentration of 9a–o, 11m, 13m, 16, 17, 23, and 24.
Comp. 9a 9b 9c 9d 9e 9f 9g 9h 9i 9l
35.9 ns 43.6 34.2 45.2 38.8 23.4 25.4 36.5 33.3
Comp. 9m 9n 9o 11m 13m 16 17 23 24
51.4 ns 39.7 ns 23.5 24.1 25.4 ns 29.1
Values are the mean of at least three independent determina-
tions; coefficient of variation was less than 15%; ns = not signifi-
cant (%-inhibition a10%).
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Discussion
An evaluation of the data reported in Table 1 revealed
that the synthesized N-(indazolyl)benzamido derivatives
9a–o are endowed with inhibitory activity against the
CDK1 ranging from 10.0 to 60.8% at 10 lM concentra-
tion. As far as structure-activity relationships are con-
cerned, it seems that the introduction of substituents in
the positions 3 and 4 of the benzamido moiety (com-
pounds 9d–m) is favorable for the CDK1 inhibition with
respect to the unsubstituted one 9a, which is scarcely
active (Table 1). Moreover, a decrease in inhibitory activ-
ity was demonstrated when the substituent in position 2
of the benzamido moiety (compounds 9b, c) is
exchanged. The displacement from the 3-position of the
indazole nucleus to the 5- and 6-positions (compounds
11m and 13m), the substitution of the benzamido moiety
with the phenoxyacetamido and phenylacetamido ones
(compounds 16 and 17), and the amidic function inver-
sion (compounds 23 and 24) gave rise to inactive or
scarcely active compounds. To rationalize the SAR
observed for N-(indazolyl)benzamido derivatives, com-
pounds 9a–o, 11m, 13m, 16, 17, 23, and 24 were docked
into the human thr160-phospho cdk2 / cyclin A (1H1S)
together with the reference inhibitor purvanalol A. Com-
parison of the different docking results of themost active
compounds 9e, f, i–n, and purvanalol A 3 shows that, in
principle, they adopt the same binding mode in the ATP-
binding cleft (Fig. 4). The ligands are oriented so that
their benzamido groups at C3 overlappes with the 3-
chloroaniline group at N6 of purvanalol A. Furthermore,
concerning the indazole nucleus, the pyrazole and phe-
nyl rings overlapped with the imidazole ring and the N9
isopropyl side chain of purvanalol A, respectively. The
most important CDK2 / purvanalol A-simulated close con-
tacts involve residues Ile10, Gly11, Gly13, Ala31, Val64,
Phe80, Glu81, Phe82, Leu83, His84, Gln85, Asp86, Lys89,
Asn132, Leu134, Ala144, Asp145, HOH5, and HOH96
while, in a similar way, CDK2-actives-simulated close con-
tacts involve residue Ile10, Gly11, Val18, Ala31, Val64,
Phe80, Glu81, Phe82, Leu83, His84, Gln85, Leu134,
HOH5, and HOH96.
As can be seen in Fig.5, according to literature data [6],
purvanalol A forms a complete triplet of hydrogen bonds
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Figure 3. Effects of compound 9m on DNA content / cell follow-
ing treatment of K562 cells for 24 h. The cells were cultured with-
out compound (control, panel a) or with 9m used at a cytostatic
concentration (panel b). Cell cycle distribution was analyzed by
the standard propidium-iodide procedure as described in the
Experimental Section. Sub-G0-G1 (A), G0-G1, S, and G2-M
cells are indicated in panel a.
Figure 4. Overlay of the docked orientation for compounds 9e, f,
i–n (white) and purvanalol A (black) docked in the human
thr160-phospho cdk2 / cyclin A (1H1S).
Figure 5. Purvanalol A (A) and compound 9m (B) docked in the
human thr160-phospho cdk2 / cyclin A (1H1S). Hydrogen bonds
are indicated as dashed lines, nitrogens are in black, oxygens
are in dark grey.
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between the N7-imidazole nitrogen and the backbone
nitrogen of Leu83 (distance = 2.20 ), the N6-amino group
and the backbone oxygen of Leu83 (distance = 2.42 ),
and the acidic C8 atom of the purine ring and the back-
bone oxygen of Glu81 (distance = 2.72 ). Compound 9m,
forms only a pair of bidentate hydrogen bonds between
the N2-indazole nitrogen and the backbone nitrogen of
Leu83 (distance = 2.17 ) and N1 indazole nitrogen and
the backbone oxygen of Glu81 (distance = 2.45 ); the
same intermolecular hydrogen bonds of 9m were
observed for all the other most active N-(indazolyl)benza-
mides 9e, f, i, l, n.
The unsubstituted derivative 9a showed a moderate
inhibitory activity against the CDK1 (22.5% at screening
concentration of 10 lM), even adopting the same binding
mode of the most active compounds 9c, f, i–n in the ATP-
binding cleft. A comparison of the Connolly surfaces of
9a, purvanalol A and the most active compounds 9c, f, i–
n showed that the presence of the substituents in the
positions 3 and 4 determines an increase of the surface in
this region with respect to the unsubstituted 9a and, con-
sequently, a greater number of positive hydrophobic
interactions with Lys89, Asp86, and Gln85.
Moreover, inactive (11m, 13m, 17, 23, 24) and scarcely
active (9a, b, c, g, n, o, 16) compounds adopt a binding
mode different from purvanalol A (Fig. 6) and form one
or no hydrogen bonds with the hinge region.
These results are in agreement with the inhibitory
activity against CDK1 reported for purvanalol A 3 and N-
(indazolyl)benzamides (Tables 1 and 2).
The in-vitro testing for compounds 9a-o, 11m, 13m, 14,
15, 21, and 22 (Table 3) indicated that the N-(indazolyl)-
benzamido derivatives are endowed with antiprolifera-
tive activity against the leukemic cell line K-562 (human
chronic myelogenus leukemia). Comparison between the
CDK1 inhibitory activity and the antiproliferative activ-
ity against K-562 showed a correlation between the two
series of data; compounds that exhibited the higher CDK
inhibition (9e, f, i–n) are, in principle, also endowed
with an antiproliferative activity against K-562 ranging
from 33.3 to 51.4% at 10 lM concentration. Finally,
although the compounds 9e, f, i–n were able to moder-
ately inhibit the leukemic cell line K-562 and to show
inhibitory activity against the Cdc2-Cyclin B kinase in
the low micromolar range, they show a very low cytotox-
icity against HuDe (IZSL), primary cell cultures from
human derm, and these preliminary results are quite
encouraging in view of the low toxicity shown by the
above-mentioned compounds. Further investigation of
the structure-activity and toxicity of this kind of com-
pounds are currently underway in our group, and results
will be published elsewhere.
Financial support from MIUR (PRIN 2006) is gratefully
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Experimental
Chemistry
Reaction progress was monitored by TLC on silica gel plates
(Merck 60, F254, 0.2 mm; Merck, Germany). Organic solutions
were dried over Na2SO4. Evaporation refers to removal of solvent
on a rotary evaporator under reduced pressure. All melting
points were determined on a Bchi 530 capillary melting point
apparatus and are uncorrected (Bchi Labortechnik, Flawil,
Switzerland). IR spectra were recorded with a Perkin Elmer Spec-
trum RXI FT-IR System spectrophotometer (Perkin-Elmer, Nor-
walk, CT, USA) as solid in KBr disc or nujol mull supported on
NaCl disks. 1H-NMR spectra were obtained using a Bruker AC-E
250-MHz spectrometer (Bruker Bioscience, USA) tetramethylsi-
lane as an internal standard): chemical shifts are expressed in d
values (ppm). Mass spectra to 70 eV were obtained using an Auto-
spec Ultima Ortogonal T.O.F.T. (Micromass, Manchester, UK)
spectrometer or a GC-MS Varian Star 3400cx Saturn III spectrom-
eter (Varian Inc., Palo Alto, CA, USA). Merck silica gel (Kiesegel
60/230–400 mesh) was used for flash chromatography columns.
Microanalyses (C, H, N) performed in the laboratories of the
Dipartimento di Scienze Farmaceutiche, Universit degli Studi
di Catania, are within l 0.4% of the theoretical values. Yields
refer to purified products and are not optimized.
General procedure for the preparation of compounds 9,
11, 13, 16, and 17
To a cold (ice bath 0–58C)magnetic stirred solution of the oppor-
tune aminoindazole 8, 10, and 12 (4.3 mmol) in pyridine
(5.37 mL), 4.3 mmol of the proper benzoyl chloride 7a–o, 14, 15
was added dropwise. The reaction mixture was left under mag-
netic stirring overnight and was then poured in crushed ice. The
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Figure 6. Overlay of the docked orientation for purvanalol A
(black) and (A) active compounds 9e, f, i–n, or inactive: (B)
compounds 9b, c, o; (C) compounds 11m, 13m; (D) compounds
16, 17; (E) compounds 23, 24.
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solid, which separated, was filtered off and crystallized to give
pure 9a–o, 11m, 13m, 16, and 17.
N-(1H-Indazol-3-yl)-2-iodobenzamide 9b
Yield: 41%; m.p.: 180–1828C (ethyl acetate / chloroform); IR (KBr)
m [cm– 1]: 3275 (NH), 1658 (CO); 1H-NMR (DMSO-d6) d [ppm]: 7.07–
7.97 (a set of signals, 8H, aromatic protons), 10.82 (s, 1H, NH,
exchangeable), 12.77 (s, 1H, NH, exchangeable). Anal.
(C14H10IN3O) C, H, N.
2-Chloro-N-(1H-indazol-3-yl)benzamide 9c
Yield: 98%; m.p.: 139–1408C (ethyl acetate / chloroform); IR (KBr)
m [cm– 1]: 3232 (NH), 1657 (CO); 1H-NMR (DMSO-d6) d [ppm]: 7.08–
7.86 (a set of signals, 8H, aromatic protons), 10.84 (s, 1H, NH,
exchangeable), 12.77 (s, 1H, NH, exchangeable). Anal.
(C14H10ClN3O) C, H, N.
3-Chloro-N-(1H-indazol-3-yl)benzamide 9d
Yield: 32%; m.p.: 165–1688C (ethyl acetate / chloroform); IR (KBr)
m [cm – 1]: 3249 (NH), 1645 (CO); 1H-NMR (DMSO-d6) d [ppm]: 7.06–
8.14 (a set of signals, 8H, aromatic protons), 10.93 (s, 1H, NH,
exchangeable), 12.84 (s, 1H, NH, exchangeable). Anal.
(C14H10ClN3O) C, H, N.
3-Bromo-N-(1H-indazol-3-yl)benzamide 1-carboxamide
9e
Yield: 67%; m.p.: 172–1758C (ethyl acetate / chloroform); IR (KBr)
m [cm– 1]: 3225 (NH), 1644 (CO); 1H-NMR (DMSO-d6) d [ppm]: 7.09–
8.27 (a set of signals, 8H, aromatic protons), 10.93 (s, 1H, NH,
exchangeable), 12.84 (s, 1H, NH, exchangeable). Anal.
(C14H10BrN3O) C, H, N.
3-Fluoro-N-(1H-indazol-3-yl)benzamide 9f
Yield: 67%; m.p.: 150–1528C (petroleum ether / chloroform); IR
(KBr) m [cm– 1]: 3196 (NH), 1637 (CO); 1H-NMR (DMSO-d6) d [ppm]:
7.07–7.96 (a set of signals, 8H, aromatic protons), 10.87 (s, 1H,
NH, exchangeable), 12.82 (s, 1H, NH, exchangeable). Anal.
(C14H10FN3O) C, H, N.
N-(1H-Indazol-3-yl)-3-methoxybenzamide 9g
Yield: 98%; m.p.: 205–2078C (ethyl acetate / chloroform); IR (KBr)
m [cm– 1]: 3282 (NH), 1651 (CO); 1H-NMR (DMSO-d6) d [ppm]: 3.85 (s,
3H, OCH3); 7.06–7.74 (a set of signals, 8H, aromatic protons),
10.75 (s, 1H, NH, exchangeable), 12.78 (s, 1H, NH, exchangeable).
Anal. (C15H13N3O2) C, H, N.
4-Chloro-N-(1H-indazol-3-yl)benzamide 9h
Yield: 72%; m.p.: 208–2108C (ethyl acetate / chloroform); IR (KBr)
m [cm– 1]: 3264 (NH), 1661, 1646 (CO); 1H-NMR (DMSO-d6) d [ppm]:
7.09–8.14 (a set of signals, 8H, aromatic protons), 10.88 (s, 1H,
NH, exchangeable), 12.82 (s, 1H, NH, exchangeable). Anal.
(C14H10ClN3O) C, H, N.
4-Fluoro-N-(1H-indazol-3-yl)benzamide 9i
Yield: 86%; m.p.: 198–1998C (ethyl acetate); IR (KBr) m [cm– 1]:
3218 (NH), 1646 (CO); 1H-NMR (DMSO-d6) d [ppm]: 7.07–8.22 (a set
of signals, 8H, aromatic protons), 10.83 (s, 1H, NH, exchange-
able), 12.82 (s, 1H, NH, exchangeable). Anal. (C14H10FN3O) C, H, N.
N-(1H-Indazol-3-yl)-4-iodobenzamide 9l
Yield: 42%; m.p.: 218–2208C (ethanol); IR (KBr) m [cm– 1]: 3256
(NH), 1647 (CO); 1H-NMR (DMSO-d6) d [ppm]: 7.06–7.95 (a set of
signals, 8H, aromatic protons), 10.83 (s, 1H, NH, exchangeable),
12.79 (s, 1H, NH, exchangeable). Anal. (C14H10IN3O) C, H, N.
3,4-Dichloro-N-(1H-indazol-3-yl)benzamide 9m
Yield: 86%; m.p.: 248–2508C (ethyl acetate / chloroform); IR (KBr)
m [cm– 1]: 3402, 3241 (NH), 1673 (CO); 1H-NMR (DMSO-d6) d [ppm]:
7.10–8.36 (a set of signals, 7H, aromatic protons), 11.00 (s, 1H,
NH, exchangeable), 12.86 (s, 1H, NH, exchangeable). Anal.
(C14H9Cl2N3O) C, H, N.
2,6-Difluoro-N-(1H-indazol-3-yl)benzamide 9n
Yield: 56%; m.p.: 190–1938C (ethyl acetate / chloroform); IR (KBr)
m [cm– 1]: 3245 (NH, NH2), 1677 (CO); 1H-NMR (DMSO-d6) d [ppm]:
7.10–7.81 (a set of signals, 7H, aromatic protons), 11.14 (s, 1H,
NH, exchangeable), 12.82 (s, 1H, NH, exchangeable). Anal.
(C14H9F2N3O) C, H, N.
3,4-Dichloro-N-(1H-indazol-5-yl)benzamide 11m
Yield: 65%; m.p.: 270–2728C (ethanol); IR (KBr) m [cm– 1]: 3266,
3153 (NH), 1634 (CO); 1H-NMR (DMSO-d6) d [ppm]: 7.54–8.21 (a set
of signals, 7H, aromatic protons), 10.40 (s, 1H, NH, exchange-
able), 13.04 (s, 1H, NH, exchangeable). Anal. (C14H9Cl2N3O) C, H,
N.
3,4-Dichloro-N-(1H-indazol-6-yl)benzamide 13m
Yield: 80%; m.p.: 270–2728C (ethanol); IR (KBr) m [cm– 1]: 3327,
3166 (NH), 1649 (CO); 1H-NMR (DMSO-d6) d [ppm]: 7.38–8.26 (a set
of signals, 7H, aromatic protons), 10.49 (s, 1H, NH, exchange-
able), 12.98 (s, 1H, NH, exchangeable). Anal. (C14H9Cl2N3O) C, H,
N.
N-(1H-Indazol-3-yl)-2-phenoxyacetamide 16
Yield: 52%; m.p.: 158–1608C (ethyl acetate / chloroform); IR (KBr)
m [cm– 1]: 3358, 3201 (NH), 1678 (CO); 1H-NMR (DMSO-d6) d [ppm]:
4.82 (s, 2H, OCH2), 6.95–7.76 (a set of signals, 9H, aromatic pro-
tons), 10.50 (s, 1H, NH, exchangeable), 12.74 (s, 1H, NH,
exchangeable). Anal. (C15H13N3O2) C, H, N.
N-(1H-indazol-3-yl)-2-phenylacetamide 17
Yield: 98%; m.p.: 229–2308C (chloroform); IR (KBr) m [cm– 1]: 3282
(NH), 1669 (CO); 1H-NMR (DMSO-d6) d [ppm]: 3.40 (s, 2H, CH2),
7.02–7.74 (a set of signals, 9H, aromatic protons), 10.62 (s, 1H,
NH, exchangeable), 12.68 (s, 1H, NH, exchangeable). Anal.
(C15H13N3O) C, H, N.
General procedure for the preparation of N-(3,4-
dichlorophenyl)-1H-indazole-3-carboxamide 23 and N-(5-
chloro-2-iodophenyl)-1H-indazole-3-carboxamide 24
A magnetically stirred solution of diindazolo[2,3-a, 2‘,39-d]pyra-
zine-7,14-dione 21 [13] (2.37 mmol, 0.68 g) and the opportune
aniline 20, 22 (4.74 mmol, 1.2 g) in pyridine (13.5 mL), was left
under magnetic stirring for seven days and then poured into
crushed ice. The solid which separated was filtered off and crys-
tallized to give the compounds 23 and 24.
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N-(3,4-Dichlorophenyl)-1H-indazole-3-carboxamide 23
Yield: 89%; m.p.: 266–2688C (petroleum ether / chloroform); IR
(KBr) m [cm– 1]: 3361, 3259 (NH), 1662 (CO); 1H-NMR (DMSO-d6) d
[ppm]: 7.31–8.36 (a set of signals, 7H, aromatic protons), 10.71 (s,
1H, NH, exchangeable), 13.88 (s, 1H, NH, exchangeable). Anal.
(C14H9Cl2N3O) C, H, N.
N-(5-Chloro-2-iodophenyl)-1H-indazole-3-carboxamide
24
Yield: 23%;m.p.: 246–2488C (ethyl acetate); IR (KBr) m[cm– 1]: 3254
(NH), 1663 (CO); 1H-NMR (DMSO-d6) d [ppm] 7.29–8.30 (a set of sig-
nals, 7H, aromatic protons), 10.69 (s, 1H, NH, exchangeable),
13.86 (s, 1H,NH, exchangeable). Anal. (C14H9ClIN3O)C,H,N.
Hardware and software
The docking experiments as well as receptor and ligand prepara-
tions were performed on a Silicon Graphics Fuel Visual Worksta-
tion (SGI, Sunnyvale, CA, USA), 1 GBmemorywith IRIX 64 release
6.5 operating system. The Insight II program 2005 (Accelrys Soft-
ware Inc., SanDiego,CA,USA)wasused for receptor and structure
manipulation and visualization of results. Cerius2 4.10 program
(Accelrys Software Inc., San Diego, CA, USA) was used for ligand
constructionand formoleculardockingprocedure.
Biology
CDK1 inhibition test
In order to estimate the inhibitory effect on individual Cdc2-
Cyclin B activity in the test compounds, we have used a “Cdc2-
Cyclin B Kinase Assay Kit” (cat#CY-1164, CycLex Co., Ltd). Plates
are pre-coated with a substrate corresponding to recombinant
Cdc7, which contains threonine residue that can be phosphory-
lated by Cdc2-Cyclin B but not Cdk2-Cyclin A, Cdk2-Cyclin E,
Cdk4-Cyclin D, and Cdk6-Cyclin D in vitro. The detector antibody
specifically detects only the phosphorylated form of threonine
residue on Cdc7.
To perform the test, the sample is diluted in kinase buffer;
10 lL of inhibitor are pipetted into the wells with 80 lL kinase
reaction buffer (kinase buffer / ATP 125 lM). To initiate reaction,
Cdc2-Cyclin B (1.5m unit/lL) is added to each well at room tem-
perature. Cdc2-Cyclin B positive control (90 lL of kinase reaction
buffer with 10 lL of Cdc2-Cyclin B, without inhibitors) should be
included in each assay as a positive control for phosphorylation.
It is also necessary to conduct the control experiment of solvent
control (80 lL of kinase reaction buffer, 10 lL of solvent for
inhibitor and 10 lL of Cdc2-Cyclin B), inhibitor control (80 lL of
kinase reaction buffer, 10 lL of 100 lM purvalanol A or an other
known inhibitor and 10 lL of Cdc2-Cyclin B) and no-enzyme con-
trol (90 lL of kinase reaction buffer with 10 lL of buffer). Cover
with plate sailer, and incubate at 308C for 30 min. We have
washed wells five times with wash buffer. The amount of phos-
phorylated substrate is measured by binding it with a 100 lL of
solution of TK-3H7, an anti-phospho-Cdc7-Threonine376 anti-
body, followed by binding with 100 lL of solution of horseradish
peroxidase conjugated anti-mouse IgG, which then catalyzed
the conversion of the chromogenic substrate tetra-methylbenzi-
dine (TMB) (100 lL of substrate reagent) from a colorless solution
to a blue solution (or yellow after the addition of 100 lL of stop-
ping reagent) (the washing with wash buffer at each step is
essential for a good performance). The color is quantitated by
spectrophotometry (at wavelength of 405 nm) and reflects the
relative amount of Cdc2-Cyclin B activity in the sample.
In-vitro antiproliferative activity
Compounds 9a–o, 11m, 13m, 16, 17, 23, and 24 were tested in
vitro for antiproliferative activity against K562 (human chronic
myelogenous leukemia) cell line. These cell lines were grown at
378C in a humidified atmosphere containing 5% CO2, in RPMI-
1640 medium supplemented with 10% fetal bovine serum and
antibiotics.
K562 cells were suspended at a density of 16105 cells/mL in
growth medium, transferred to 24-well plate (1 mL/well), cul-
tured with or without (in the case of control wells) a screening
concentration of 10 lM of compounds and incubated at 378C for
48 h. Numbers of viable cells were determined by counting in a
hematocytometer after dye exclusion with trypan blue [23]. The
antiproliferative effects of the compounds were estimated in
terms of%-growth inhibition comparing cell viability of treated
and untreated cells. We determined IC50 values (test agent con-
centration at which the cell proliferation was inhibited to 50%
of the untreated growth control) for compounds that exhibited
the best activity at the screening concentration.
Cytotoxicity for normal cells
We evaluated the cytotoxicity of compounds 9e, f, i–m against
HuDe (IZSL), primary cell cultures from human derm; such activ-
ity was determined byMTT (methylthiazotetrazolium) assay [24].
The cells were suspended at a density of 16105 cells/mL in MEM
(Sigma, USA), supplemented with 10% fetal calf serum and anti-
biotics, transferred (100 lL/well) to 96-well plate, and incubated
at 378C for three days until the formation of a cellular mono-
layer. After this time, the original medium was replaced with
RPMI-1640 medium without red phenol (Sigma) and concentra-
tions ranging from 100 to 1 lM of compounds were added to
each well and incubated at 378C for 24 h. The cytotoxic effects of
the compounds were estimated in term of%-growth inhibition
comparing cell viability of treated and untreated cells by their
reduction of the tetrazolium substrate and IC50 values (test agent
concentration at which the cell proliferation was inhibited to
50% of the untreated growth control) were determined.
Flow-cytometric analysis of cell-cycle distribution
The effects of compound 9m on cell-cycle distribution were stud-
ied on K562 cells (myeloblastic leukemia) by flow-cytometric
analysis after staining with propidium iodide. Cells were
exposed 24 h to compound 9m. After treatment, cells were
washed once in ice-cold phosphate buffered salinemedium (PBS;
Sigma) and resuspended at 106/mL in a hypotonic fluorochrome
solution of propidium iodide (Sigma, St Louis, MO, USA) (50 lg/
mL) and nonidet P-40 (Sigma) [0.03% (v/v)] in 0.1% sodium citrate.
After 30 min of incubation, the fluorescence of each sample was
analyzed as single-parameter frequency histograms by using a
FACScan flow cytometer (Becton Dickinson, San Jose, CA, USA).
The distribution of cells in the cell cycle and the apoptotic
subG0-G1 peak was analyzed with the ModFit LT3 program
(Verity Software House, Inc., Topsham, ME, USA).
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